Company profile: TAE Life Sciences
1.1 - Company Overview
Company description
- Provider of biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT), offering the Alphabeam compact hospital-use tandem accelerator neutron source, BNCT combining boron-10 drugs and neutron beams to selectively destroy cancer cells, and TC220, a boronated amino acid analog targeting cancers including GBM, breast, and melanoma; the only company with comprehensive target drug and neutron technology product.
Products and services
- Boron Neutron Capture Therapy (BNCT): Isotope-specific, biologically-targeted radiation therapy combining boron-10 drugs and neutron beams to selectively destroy cancer cells in rapidly spreading, invasive, recurrent, therapy-resistant tumors
- Alphabeam System: Hospital-grade compact tandem accelerator-based neutron source architected for hospital use, enabling BNCT treatments on-site as TLS’s neutron technology product
- TC220: Boronated amino acid analog drug for BNCT, targeting GBM, breast, and melanoma by conveying boron-10 to malignant cells prior neutron beam exposure
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to TAE Life Sciences
Vaxess
HQ: United States
Website
- Description: Provider of needle-free vaccine and therapeutic delivery solutions, offering the MIMIX applicator with patch for skin-based administration and silk fibroin biomaterials that create stable, biocompatible delivery systems, with a focus on improving access to vaccines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vaxess company profile →
Nkarta
HQ: United States
Website
- Description: Provider of a cell engineering platform for next-generation cell therapies, offering allogeneic off-the-shelf CAR-NK treatments including NKX101, an NKG2D CAR-NK for hematologic malignancies and solid tumors, and NKX019, a CD19-targeting CAR-NK for B-cell malignancies, supported by a proprietary allogeneic manufacturing process for NK cell collection, activation, engineering, expansion, and cryopreservation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nkarta company profile →
Shasqi
HQ: United States
Website
- Description: Provider of a click chemistry-based technology platform (CAPAC) that activates cancer drugs at the tumor site to minimize toxicity and improve outcomes; developer of SQ3370, a clinically validated asset that activates a doxorubicin protodrug with demonstrated safety and efficacy in advanced soft tissue sarcoma; offers antigen-targeting activators and protodrugs for payloads like monoclonal antibodies and traditional chemotherapy agents; in research collaboration with Johnson & Johnson.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Shasqi company profile →
EsoBiotec
HQ: Belgium
Website
- Description: Provider of biotechnology solutions focused on the discovery of novel cancer therapies, aiming to enable the human body to fight cancer through in vivo cell engineering.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EsoBiotec company profile →
Immunicum
HQ: Sweden
Website
- Description: Provider of clinical phase II cancer immunotherapies, including therapeutic cancer vaccines and T-cell expansion methods rooted in transplantation immunology. Offerings include Vididencel, a maintenance therapy for measurable residual disease in AML and ovarian cancer; Ilixadencel, an intratumoral immune primer of pro-inflammatory donor dendritic cells for combination treatment of hard-to-treat solid tumors; and a preclinical memory NK-cell expansion platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunicum company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for TAE Life Sciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to TAE Life Sciences
2.2 - Growth funds investing in similar companies to TAE Life Sciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for TAE Life Sciences
4.2 - Public trading comparable groups for TAE Life Sciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →